Latest Breaking News On - Platinum resistant ovarian cancer - Page 3 : comparemela.com

Notable ASCO Trial Data Have the Potential to Transform Oncology Pharmacy Practice

These study results may inform clinical practice strategies this year and beyond.

United statesLarry kimmonsDennisj slamonEmily kuhlSara fagerlieMedimmune astra zenecaAstellas pharmaAaron tallentKara nybergServier pharmaceuticalsDepartment of gastrointestinal medical oncologyAccess to oncology medicines coalitionUniversity of texas md anderson cancer centerJanssen pressDepartment of investigational cancer therapeuticsAmerican society of clinical oncology

Corcept Therapeutics (CORT) Announces Journal of Clinical Oncology Publishes Results of Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer

Corcept Therapeutics (CORT) Announces Journal of Clinical Oncology Publishes Results of Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDevelopment officerCorcept therapeutics incorporatedOvarian cancer centerAmerican society of clinical oncologyUniversity of milanProgram of gynecologyEuropean institute of oncologyClinical oncologyAmerican societyPlatinum resistant ovarian cancerOpen label phaseNicoletta colomboAssociate professorEuropean instituteBill guyer

StreetInsider com - FDA News

StreetInsider com - FDA News
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hong kongFast track designation for developmentAmeli lilly coAmcue health incBriefing documents ahead of panelProgram for mirikizumabWatch afterBriefing documents aheadProvide coronavacSelf paying customersMakes de novo submissionFull clearanceFast track designationPlatinum resistant ovarian cancerReports interim phasePediatric patients

FDA Grants Fast Track Designation to ACR-368 in Platinum-resistant Ovarian Cancer and Endometrial Cancer

The FDA has granted fast track designations to ACR-368 monotherapy for the treatment of patients with platinum-resistant ovarian cancer and endometrial cancer who are positive for predicted sensitivity to the agent using Acrivon Therapeutics’ OncoSignature® test.

Acrivon oncosignaturePeter blume jensenInternational federation of gynecologyAcrivon therapeutic oncosignatureFast trackCheckpoint kinaseFast track designationAcr 368Platinum resistant ovarian cancerEndometrial cancer

ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer Resul

ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer   Results Show Statistically Significant Improvements in PFS, ORR, and OS Compared to Chemotherapy First Medicine to Demonstrate an Overall Survival Adv.

United statesUniversity of oklahomaMark enyedyKathleen mooreAnna berkenblitSarah cannon phasei programEuropean medicines agencyImmunogen incClinical researchDrug administrationDemonstrates overall survival benefitPositive platinum resistant ovarian cancerShow statistically significant improvementsOverall survival advantagePlatinum resistant ovarian cancerMarketing authorization application